Priority Review for Teva's fremanezumab to treat migraine

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said FDA accepted and granted Priority Review to a BLA for fremanezumab (TEV-48125) to prevent migraine.

Teva said it submitted a

Read the full 272 word article

User Sign In